Repligen (RGEN) Misses Q2 EPS by 2c

Repligen (NASDAQ: RGEN) reported Q2 EPS of $0.16, $0.02 worse than the analyst estimate of $0.18. Revenue for the quarter came in at $47.7 million versus the consensus estimate of $46.08 million.

GUIDANCE:

Repligen sees FY2018 EPS of $0.69-$0.73, versus the consensus of $0.71. Repligen sees FY2018 revenue of $185-190 million, versus the consensus of $185.35 million.

For earnings history and earnings-related data on Repligen (RGEN) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Boost Run, Inc. (BRUN) Reports Q2 Revenue of $31.1M
• Rein Therapeutics Inc. (RNTX) Tops Q2 EPS by 39c